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Abstract
Background: Chronic kidney disease is asymptomatic until its last stages and though it is increasing globally,
we are faced with paucity of a population-based model to assess this disease, particularly in developing coun-
tries. Therefore, the aim of this study was to estimate the prevalence and trends of CKD according to a new es-
timation method.
Methods: Using multiplier method, we estimated the numbers of different stages of CKD based on the number
of patients with end stage renal failure from 2006 to 2016. The required multipliers were extracted from a simu-
lation of the disease in Kerman following a dynamic model. The 95% uncertainty interval was computed using
Monte-Carlo technique with 10,000 iterations.
Results: The prevalence of CKDA (GFR<=90mL/min/1.73m2) and CKDB (GFR less than 60mL/min/1.73m2)
patients were estimated to be 7.6% (95% uncertainty interval (UI), 5.7-9.1%) and 1.1% (95% UI, 0.8-1.3%),
respectively in 2011. The method revealed that the prevalence may rise up to 25.7% (95% UI, 18.2-32.5%) and
3.7% (95% UI, 2.7-4.5%) for CKDA and CKDB, respectively in 2016, indicating approximately 3.3 times in-
crease for both figures.
Conclusion: This study predicted an increase in the prevalence of CKD in the future. This may be due to the
increasing life expectancy of the population, the increase in the prevalence of non- communicable diseases such
as hypertension and diabetes, or patients’ survival due to receiving better support. Therefore, the policymakers
should be concerned and well informed about this increase.
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Introduction
Chronic kidney disease (CKD) is a major
health problem (1). The progress of CKD is
usually smooth and without any significant
symptoms until the last stage when the pa-
tient may only survive with either dialysis
or kidney transplant (2-3).
National Health and Nutrition Evaluation
Survey in the U.S. has demonstrated that
the prevalence of CKD (except for ESRF)
has risen from 10% in 1994-1998 to 13.1%
in 199 9-2004 (4). Based on the annual re-
port of United Network for Organ Sharing
in 2002, among patients who enroll in daily
waiting list, 16 would die and one  would
need kidney transplant every 15 minutes
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(5). More than 1.1 million ESRF patients
have an annual increasing rate of 7%
worldwide. It is predicted that more than
70% of the ESRF patients will be residents
of the developing countries (6-7). Due to
the aging of the societies and the high prev-
alence of predisposing chronic diseases
such as diabetes mellitus and hypertension,
the number of CKD cases has noticeably
raised in the past years (8-9).
A few studies estimated the number of
ESRF and CKD patients in Iran. According
to the reports from the Management Center
for Transplantation and Special Diseases
(Ministry of Health), the number of regis-
tered ESRF patients was 24,000 and 40,000
in 2004 and 2009, respectively, which is a
dramatic increase (10-11). In a study con-
ducted in Iran, it was estimated that over
700, 000 people had CKD, and 61, 000 new
cases of CKD would have been developed
by 2004 (11-12). Different studies in Iran
reported 6 to 17% prevalence for CKD
(10). The discrepancy among these figures
might be due to the differences in their
methodologies, mainly sampling and renal
failure verification techniques. Because
CKD is usually asymptomatic, determining
its prevalence using direct methods might
be an underestimation (2). Therefore, using
indirect methods and models may help to
illustrate the level of the disease efficiently.
Different indirect methods, including the
multiplier method, have been employed to
estimate the prevalence of diseases (13).
The multiplier method has been frequently
used to estimate the size of hidden sub-
populations such as female workers and
injecting drug users (14). However, to the
best of our knowledge, no study has esti-
mated the prevalence of CKD using multi-
plier method in in Iran.
One of the advantages of this method is
its ability to estimate the prevalence of the
disease in different age groups, sexes and
stages.  Due to a paucity of population-based
model to estimate CKD, the aim of this study
was to implement a new and simple statistical
model to estimate the prevalence and trends
of CKD with accuracy.
Methods
Study Setting and Definition: This study
used indirect methods based on the data
gathered from Kerman, the largest province
in southeast of Iran, with a population of
around 620,000 and a dry climate.
In this study, CKD is defined as” abnor-
malities of kidney, structure or function,
present for>3 months, with implications for
health; and CKD is classified based on
cause, glomerular filtration rate category,
and albuminuria category (CGA)”. Based
on GFR category, there are five stages for
CKD. These stages are determined accord-
ing to the level of GFR and kidney damage.
The total number of CKD was estimated
for the two conditions: Stages one to five
(GFR <=90 mL/min/1.73 m2), and stages
three to five (GFR less than 60
mL/min/1.73 m2). We used the term CKDAand CKDB for these conditions, respective-ly (15-17).
Multiplier Method: The multiplier meth-
od was used to estimate the number of
CKD cases among those aged over 20 in
Kerman.  Multiplier method is an indirect
method that needs two parameters: Bench-
mark and multiplier. Benchmark parameter
is defined as the number of persons who
registered in the target centers (Bi) in a cer-tain period of time,, so we used the totalnumber of registered ESRF patients in
Kerman as benchmark (Bi). In this context,multiplier parameters (mi) are the ratio ofthe size of each stage of the disease to the
size of its pervious stage; for example, m1
Fig. 1. Schematic of CKD (16) Estimation Method
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is the size of ESRF over the size of patients
in stage 5 (Fig. 1).
Bi parameter: The number of patientswith hemodialysis and peritoneal dialysis
or a kidney transplant was considered as
the benchmark parameter in the first
benchmark (B1). Data were obtained basedon census sampling method from all of di-
alysis and kidney transplant centers in
Kerman. From 2006 to 2011, patients were
classified by age group: 20-39, 40-59, <=60
years, and were counted. Then the number
of patients was estimated in each stage and
considered as a benchmark parameter for
the next stage. For example, to estimate the
number of people in stage 5, the number of
ESRD patients who underwent renal re-
placement therapy (RRT) such as dialysis
or kidney transplant was used as the
benchmark parameter during the study (the
proportion of ESRF patients of this study to
the number of patients in stage 5). In this
study, the number of patients in stage 5 was
estimated using multiplier method. Moreo-
ver, this number (the number of patients
estimated in stage 5) was considered as a
benchmark parameter for estimating the
number of patients in the previous stage
(stage 4). In addition, the number of pa-
tients in stage 4 has been estimated consid-
ering the multiplier parameter of stage 4
(the proportion of stage 5 to stage 4).
Moreover, the number of patients in all
stages of CKDA and CKDB have been esti-mated with respect to the multiplier param-
eters and benchmark  number in each stage.
mi parameter: Due to the lack of access tomultiplier parameters, a dynamic model
was designed to simulate the parameters.
The dynamic model requires reasonable
inputs including age-specific annual inci-
dence, death rate, and disease progression,
which were estimated in each stage (18-
20). Thus, a systematic review was con-
ducted to obtain the above-mentioned in-
puts (Table 1). Unfortunately, no infor-
mation was available on the inputs of age
and stage of the disease in Iran; therefore,
the literature of other countries was used.
However, the validity of the finding about
the input has been discussed during the
group discussions with epidemiologists and
interviews with experts. In addition, we
tried to provide the lowest bias and highest
accuracy for the impact of uncertainty in
the inputs using statistical methods such as
sensitivity analysis.
In this model, we assumed that the dis-
ease has started in the past and reached a
stable trend over time. Moreover, we as-
sumed that individuals were mixed in a
random order, the population size was con-
stant and the incidence, mortality and pro-
gression stages remained invariant over
Table 1. Inputs used in the Model to Simulate the Multiplier Parameters
Inputs
Value used (%) Reference
number
Stage1 Stage2 Stage3 Stage4 Stage5Age-group 20-39
Rate* of ESRF in different stages of CKD 0.02 0.02 1.7 20.2 67.4 (19)
Rate** of disease progression in different
stages of CKD
20 12 6 13 12 (20)
Rate** of death in different stages of CKD 7 12 21 35 15 (20)
Rate of death in ESRF under RRT 8.8 (21)
Age-group40-59
Rate of ESRF in different stages of CKD 0.03 0.03 0.97 15.7 79.5 (19)
Rate of death in ESRF under RRT 16.2 (21)
Age-group>=60
Rate of ESRF in different stages of CKD 0.03 0.03 0.37 7.2 4.6 (19)
Rate of death in ESRF under RRT 34.4 (21)
Output (multiplier parameter) m1 m2 m3 m1 m5Multiplier parameter in the age-group 20-39 86 18 46 6 863
Multiplier parameter in the age-group 40-59 64 27 32 10 473
Multiplier parameter in the age>=60 29 67 18 19 134
*Annual Rate, **Due to the inaccessibility to the proper data, it was considered similar in all age groups.
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time. Based on the results of the dynamic
model, a period of at least 20 years was re-
quired to reach a stable trend. Therefore,
the dynamic model was developed based on
the period from 1991 to 2011. The number
of participants in each stage (1 to 5), and
the multiplier parameters were subsequent-
ly calculated using "solver" commend in
Excel (Table 1).
Sensitivity Analysis
Monte Carlo method was applied with
10,000 iterations in Stata Version 11 to
provide 95% uncertainty interval (UI). We
used normal distribution for all the parame-
ters, which were derived from the dynamic
model. The range between 2.5 and 97.5
percentiles was considered as 95% UI.
Results
Overall, from 2006 to 2011, 963 new
Kermanian ESRF cases were registered (78
in 2006, 101 in 2007, 127 in 2008, 168 in
2009, 216 in 2010, and 273 in 2011). The
annual growth rate was 28%; of which,
around 15% were 20-39 year olds, 37%
were 40-59, and 48% were over 60 years of
age.
The Number and Prevalence Rate of CKD
in a Population of Older than 20 Years of
Age
The estimated number of CKDA andCKDB patients was 33,617 and 4,990, re-spectively in 2011 (Table 2 and Fig. 2). The
estimated prevalence for this year was
7,668 for CKDA and 1,138 for CKDB. Our
Fig. 2. The predicted prevalence of CKDA (1) and CKDB (2) per 100,000 population* Graphs include 95% uncertainty interval
Table 2. The Number and Prevalence of CKDA and CKDB Classified by Age Group and Year
Age Groups, Year
CKDA CKDB
2006 (95% UI) 2011 (95% UI) 2016 (95% UI) 2006 (95% UI) 2011 (95% UI) 2016 (95% UI)
Number
20- 39 822
(549-1055)
2470
(1775-3171)
11231
(7055-15962)
103
(80-124)
307
(239-375)
1125
(828-1387)
40- 59 2140
(1543-2728)
7580
(5443-9714)
31096
(20554-41554)
290
(220-359)
1031
(773-1284)
3900
(2789-4891)
>=60 6143
(4216-8109)
21562
(15648-29607)
38936
(32256-42786)
974
(702-1243)
3769
(2550-4584)
11892
(8546-14586)
All >=20 9100
(7059-11139)
33617
(25247-40032)
124315
(88280-157325)
1365
(1088-1643)
4990
(3857-5955)
17947(13308-
21846)
Prevalence
(per 100,000
population)
20- 39 354
(256-455)
958
(658-1175)
3943
(2477-5604)
44
(34-53)
114
(89-139)
359
(291-487)
40- 59 2030
(1464-2588)
5979
(4222-7534)
20735
(13705-27708)
257
(209-341)
800
(600-996)
2601
(1860-3261)
>=60 17390
(11935-22955)
53061
(39575-74879)
80550
(66730-88514)
2757
(1987-3519)
9038
(6449-11593)
24601
(17683-30175)
All >=20 2442
(1894-2989)
7668
(5759-9131)
25731
(18272-32563)
366
(292-441)
1138
(880-1358)
3715
(2755-4522)
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results revealed that the estimated preva-
lence was three times more in 2011 com-
pared to 2006. Moreover, the predicted
number of patients was 124,315 for CKDAand 17,947 for CKDB for 2016. The corre-sponding prevalence was 25,731 and 3,715
per 100,000 population aged over 20 (Fig.
2).
The Prevalence of CKDA Classified byAge Group
In all age groups, the estimations for 2011
were about three times the estimations in
2006 (Fig. 3). The prevalence of CKDAamong 20-39 year-olds was 985 in 2011,
which was 2.7 times more compared to
2006. The prevalence of the disease was
5,997 in 40-59 age group in 2011, which
was 2.9 times more than that in 2006. The
corresponding ratio for>=60 year-olds was
3.5. Our prediction indicate that in 2016 the
prevalence of CKDA will be 3,943, 20,735,and 80,550 for the 20-39, 40-59, and>=60
age groups, respectively (Fig. 3).
The Prevalence of CKDB Classified byAge Group
Prevalence of CKDB was 114 among the20-39 year-olds in 2011, indicating a 2.5
times increase compared to 2006. A com-
parison of the prevalence of CKDB among40-59 year old individuals during these
years shows a 3.1 time increase (257 vs.
800). The corresponding ratio for>=60
year-olds was 3.2 (Fig. 3 and Table 2). Our
prediction shows that in 2016 the values
will be nearly three times the values in
2011 in all age groups (Table 2).
Relationship between Age and CKDA/CKDB PrevalenceOur results revealed that the prevalence
of CKDA and CKDB increased with age(Table 2). In 2006, 2011, and 2016, the
prevalence of CKDA was at least five timeshigher in 40-59 year olds than those aged
20-39. Based on the estimated values for
2011 and 2006, the prevalence of the dis-
ease among those aged>=60 was around
Fig. 3. The prevalence of CKDA and CKDB per 100,000 populations in different age groups, with 95% uncertaintyinterval
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eight times higher than those aged 40-59.
The corresponding figure for 2016 was four
times as much (8,055 vs. 20,735). The
prevalence of CKDB among patients aged40- 59 was about six times higher than 20-
39 year-olds. Comparing>=60 to 40-59
year-olds, the corresponding figure was
about ten times as much, which was more
or less constant over time.
Discussion
The results of this study revealed that
there would be an increase in the preva-
lence of CKDA and CKDB in Kerman andthis is predicted to maintain in the future. In
addition, we estimated a higher rate of the
disease in older age groups. The prevalence
of CKDA and CKDB was 7.6% and 1.1% in2011, respectively. These prevalence fig-
ures are nearly three times more than those
reported in 2006. These disorders are pro-
jected to increase in a rate of 3.3 in 2016
compared to the corresponding figures in
2011.
The prevalence of the disease was very
different globally. The minimum and max-
imum reported CKDA were 6.3% and26.7% worldwide, while CKDB was report-ed to be 1.3 % and 18.9 % (3, 21-22). Re-
cent studies in Iran reported different
prevalence for CKDA and CKDB. Hosse-inpanah and colleagues reported a 18.9%
prevalence for CKDB in Iran (23). In astudy  conducted in Kalaleh (in northern
Iran), the prevalence of CKDB was reportedto be  8.8% (10). In a study in Tehran, the
capital of Iran, the prevalence of CKDB was6.5%  among taxi drivers (6).
The differences between the prevalence
estimated in the present study and other
studies might be either due to the differ-
ences in the genetic factors, environmental
effects, lifestyle, socioeconomic status of
the society, and access to health care ser-
vices. Furthermore, these differences could
be due to  the demographic pattern of the
samples and different methodologies em-
ployed (10). Methodological differences
are either in the serum creatinine measure-
ment methods, the formula used to estimate
GFR, or  in the definition of albuminuria
and proteinuria to diagnose CKDA andCKDB in different studies .(24). For in-stance, in a study by Eynollahi and col-
leagues in Tehran, they measured the renal
function in the first step, and estimated the
prevalence of CKDB to be 4.6%. However,when they rechecked the patients to con-
firm the disease, they found a 2% preva-
lence (25). The noticeable point is that the
studies performed in Iran mainly used a
single measurement to detect patients, and
the MDRD formula is used without ethnic
coefficient which could lead to the overes-
timation of the results.
However, a sharp time trend exists in the
prevalence of this disease; therefore, the
measured frequency of the disease might
vary in different studies only due to a few
year time intervals between the studies. In
terms of the time trend of the disease, an
increasing trend has been observed in most
studies throughout the world, similar to our
results. The increasing trend  could be ex-
plained through the aging of the population
and propagation of chronic diseases such as
diabetes mellitus, hypertension,
dyslipidemia, or  it might be due to the
higher existence of risk factors such as
BMI imbalance, lack of physical activity,
and ethnic and genetic factors (14,26). Be-
cause these factors are increasing, we may
witness a higher rate of CKDA and CKDBin the future. However, a part of these
growths might be due to the improvement
of the diagnosis tests and the availability of
heath care services such as dialysis centers,
kidney transplant centers, and nephrologists
(4).
A positive correlation was found between
age and the prevalence of the disease. Most
of the patients were older than 60 years,
similar to other studies (27); for example
CKDA was eight times higher in>60 year-olds than in 40-59 year-olds, and CKDBprevalence was 10 times higher in the>60
age groups than in 40-59 year-olds. Based
on the  prior studies across the world, we
observed that the minimum and maximum
prevalence of CKDA was reported to be 1-
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2.7% (27-28), 7.6-29.6% (10,28), and 23.4-
38.3% (28-29) in 20-39, and 40-59 age
groups and in population of over 60 years
of age, respectively. Similarly for CKDB,the minimum and maximum prevalence
was 0.3-7% (30-31), 1.4-6.2% (31-32), and
8.14-23.59% (1,30), respectively. This
could be explained through the reduction of
renal function and the higher chance in oc-
currences of other risk factors associated
with age increase (33-34) such as cardio-
vascular disease (CVD), diabetes, and hy-
pertension.
Although this study was the first to apply
an indirect method to estimate and predict
the prevalence of CKDA and CKDB, it hassome limitations. Like other prediction
methods, the precision and validity of out-
puts depend on the model’s assumptions. In
addition, we might have missed some pa-
tients due to death before being admitted to
dialysis and kidney transplant centers, and
this could affect the benchmark parameter.
However, changes in these numbers may
not be significant because ESRF has obvi-
ous symptoms.
The policymakers in the National Health
System in Iran should pay more attention to
the early detection (screening) and man-
agement of these diseases. Moreover, this
disease has an iceberg pattern. Thus, only a
small proportion of patients with chronic
kidney diseases have tangible and visible
symptoms. As indicated in this study, many
patients will reach higher stages of chronic
kidney failure, and this supports our as-
sumption that many people with ESRD will
be unveiled.
We need a coherent plan to provide facili-
ties, medical equipment (such as space,
equipment, and beds for dialysis or trans-
plantation) and the labor force necessary to
respond to the patients' demands. In addi-
tion, the hidden and large part of the popu-
lation will increase continually for reasons
such as the increases of the general popula-
tion's life expectancy, and the prevalence of
chronic diseases like diabetes and high
blood pressure. As a result, detection and
diagnosis of these screening programs
should be taken into account to delay or
even prevent the progression of the disease
to the end-stage renal failure.
Conclusion
This study was the first modeling study of
CKD prevalence in Iran. The results of this
study revealed that this disease might have
a notable prevalence in the next few years,
which would be more significant in older
age groups. Therefore, there is an increas-
ing need to develop services to provide ap-
propriate care and treatment for the in-
creased number of patients. Furthermore,
annual or national screening of this disease
should be implemented in the high-risk
population, especially in the elderly.
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